Literature DB >> 24121758

Discordance between peripheral and colonic markers of inflammation during suppressive ART.

Richard M Dunham1, Ivan Vujkovic-Cvijin, Steven A Yukl, Mara J Broadhurst, Pʼng Loke, Rebecca G Albright, Joseph K Wong, Michael M Lederman, Ma Somsouk, Peter W Hunt, Jeffrey N Martin, Steven G Deeks, Joseph M McCune.   

Abstract

OBJECTIVE: Persistent systemic inflammation is associated with the inability of some HIV-infected patients to normalize circulating CD4 T-cell levels after years of suppressive antiretroviral therapy. In this study, we sought to understand whether such systemic inflammation is also associated with detectable signs of inflammation in biopsies from the rectosigmoid colon.
DESIGN: Immunologic and virological parameters were studied in the peripheral blood and in rectosigmoid colon biopsies from individuals with viral suppression for at least 2 years and with peripheral CD4 T-cell levels of <350 cells per cubic millimeter (immunologic nonresponders, n = 18) or >500 cells per cubic millimeter (immunologic responders, n = 16).
METHODS: Peripheral blood and rectosigmoid colon biopsies were analyzed by flow cytometry, enzyme-linked immunosorbent assay, and quantitative polymerase chain reaction.
RESULTS: Nonresponders had elevated T-cell activation and inflammatory cytokines in the circulation, but inflammatory gene expression in colon biopsies was not different as compared with responders, and there was little relationship between blood and colon markers of inflammation. Blood inflammatory markers were positively associated with soluble CD14 levels indicative of monocyte activation.
CONCLUSIONS: These findings demonstrate that, in the context of treated HIV disease, it is easier to detect parameters of inflammation (including blood monocyte activation) in the peripheral blood than in isolated rectosigmoid colon biopsies. Accordingly, interventions to block such inflammation in this population might be most conveniently and accurately assessed in blood.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24121758      PMCID: PMC3997573          DOI: 10.1097/01.qai.0000437172.08127.0b

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  42 in total

1.  'Modeling' relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses.

Authors:  M M Lederman; L A Kalish; D Asmuth; E Fiebig; M Mileno; M P Busch
Journal:  AIDS       Date:  2000-05-26       Impact factor: 4.177

2.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

3.  Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy.

Authors:  Tae-Wook Chun; J Shawn Justement; Punita Pandya; Claire W Hallahan; Mary McLaughlin; Shuying Liu; Linda A Ehler; Colin Kovacs; Anthony S Fauci
Journal:  J Infect Dis       Date:  2002-05-08       Impact factor: 5.226

4.  Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.

Authors:  Moraima Guadalupe; Elizabeth Reay; Sumathi Sankaran; Thomas Prindiville; Jason Flamm; Andrew McNeil; Satya Dandekar
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.

Authors:  Xinyan Zhang; Peter W Hunt; Scott M Hammer; Michelle S Cespedes; Kristine B Patterson; Ronald J Bosch
Journal:  HIV Clin Trials       Date:  2013 Mar-Apr

6.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.

Authors:  Steven G Deeks; Christina M R Kitchen; Lea Liu; Hua Guo; Ron Gascon; Amy B Narváez; Peter Hunt; Jeffrey N Martin; James O Kahn; Jay Levy; Michael S McGrath; Frederick M Hecht
Journal:  Blood       Date:  2004-04-29       Impact factor: 22.113

7.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Authors:  Peter W Hunt; Jeffrey N Martin; Elizabeth Sinclair; Barry Bredt; Elilta Hagos; Harry Lampiris; Steven G Deeks
Journal:  J Infect Dis       Date:  2003-04-23       Impact factor: 5.226

8.  Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection.

Authors:  A Kalinkovich; H Engelmann; N Harpaz; R Burstein; V Barak; I Kalickman; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

9.  Human monocyte CD14 is upregulated by lipopolysaccharide.

Authors:  R Landmann; H P Knopf; S Link; S Sansano; R Schumann; W Zimmerli
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  15 in total

1.  Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection.

Authors:  Liang Cheng; Haisheng Yu; Guangming Li; Feng Li; Jianping Ma; Jingyun Li; Liqun Chi; Liguo Zhang; Lishan Su
Journal:  JCI Insight       Date:  2017-06-15

2.  Gut epithelial barrier and systemic inflammation during chronic HIV infection.

Authors:  Ma Somsouk; Jacob D Estes; Claire Deleage; Richard M Dunham; Rebecca Albright; John M Inadomi; Jeffrey N Martin; Steven G Deeks; Joseph M McCune; Peter W Hunt
Journal:  AIDS       Date:  2015-01-02       Impact factor: 4.177

Review 3.  Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice.

Authors:  Lishan Su
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

4.  Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Jianping Ma; Jingyun Li; Dan Li; Guangming Li; Feng Li; Qing Zhang; Haisheng Yu; Fumihiko Yasui; Chaobaihui Ye; Li-Chung Tsao; Zhiyuan Hu; Lishan Su; Liguo Zhang
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

5.  The interferon paradox: can inhibiting an antiviral mechanism advance an HIV cure?

Authors:  Steven G Deeks; Pamela M Odorizzi; Rafick-Pierre Sekaly
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

6.  Impact of early cART in the gut during acute HIV infection.

Authors:  Claire Deleage; Alexandra Schuetz; W Gregory Alvord; Leslie Johnston; Xing-Pei Hao; David R Morcock; Rungsun Rerknimitr; James L K Fletcher; Suwanna Puttamaswin; Nittaya Phanuphak; Robin Dewar; Joseph M McCune; Irini Sereti; Merlin Robb; Jerome H Kim; Timothy W Schacker; Peter Hunt; Jeffrey D Lifson; Jintanat Ananworanich; Jacob D Estes
Journal:  JCI Insight       Date:  2016-07-07

7.  Proteome and Protein Network Analyses of Memory T Cells Find Altered Translation and Cell Stress Signaling in Treated Human Immunodeficiency Virus Patients Exhibiting Poor CD4 Recovery.

Authors:  Sausan Azzam; Daniela Schlatzer; Sean Maxwell; Xiaolin Li; Douglas Bazdar; Yanwen Chen; Robert Asaad; Jill Barnholtz-Sloan; Mark R Chance; Scott F Sieg
Journal:  Open Forum Infect Dis       Date:  2016-03-15       Impact factor: 3.835

8.  Systemic Cytokine Levels Do Not Predict CD4(+) T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection.

Authors:  Philip J Norris; Jinbing Zhang; Andrew Worlock; Sangeetha V Nair; Kathryn Anastos; Howard L Minkoff; Maria C Villacres; Mary Young; Ruth M Greenblatt; Seema Desai; Alan L Landay; Stephen J Gange; C Thomas Nugent; Elizabeth T Golub; Sheila M Keating
Journal:  Open Forum Infect Dis       Date:  2016-02-08       Impact factor: 3.835

9.  HBV and HIV viral load but not microbial translocation or immune activation are associated with liver fibrosis among patients in South Africa.

Authors:  Tongai Gibson Maponga; Monique I Andersson; Christoffel J van Rensburg; Joop E Arends; Jantjie Taljaard; Wolfgang Preiser; Richard H Glashoff
Journal:  BMC Infect Dis       Date:  2018-05-08       Impact factor: 3.090

10.  Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.

Authors:  Vincent C Marconi; Carlee Moser; Christina Gavegnano; Steven G Deeks; Michael M Lederman; Edgar T Overton; Athe Tsibris; Peter W Hunt; Amy Kantor; Rafick-Pierre Sekaly; Randall Tressler; Charles Flexner; Selwyn J Hurwitz; Daniela Moisi; Brian Clagett; William R Hardin; Carlos Del Rio; Raymond F Schinazi; Jeffrey J Lennox
Journal:  Clin Infect Dis       Date:  2022-01-07       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.